Home / Oncology (page 158)

Oncology

City of Hope and Fortress Biotech Form DiaVax Biosciences to Develop New Vaccines

A new company has been formed to develop two novel vaccines against cytomegalovirus (CMV) infection, a life-threatening illness in people with weakened or underdeveloped immune systems, such as cancer patients and developing fetuses. City of Hope and Fortress Biotech have reached an agreement to form the new subsidiary company, called …

Read More »

Baxter and Merrimack File for Approval of its Pancreatic Cancer Drug in Europe

Today, Baxter Bioscience and Merrimack Pharmaceuticals announced that the companies have submitted a marketing authorization application (MAA) for approval of its investigational treatment for patients with pancreatic cancer in Europe. The companies said that they have submitted an application to the European Medicines Agency (EMA) for approval of MM-398, also …

Read More »

Biocept Launches its c-MET Biomarker

Molecular oncology diagnostics company, Biocept, Inc., is expanding its cancer diagnostic portfolio with the launch of a new liquid biopsy detection test. The company announced the launch of its c-MET amplification detection test utilizing a blood-based “liquid biopsy.” According to the company, the diagnostic assay can potentially help physicians identify …

Read More »

FDA Panel Recommends Approval of Amgen’s T-Vec in Melanoma

This week the US Food and Drug Administration (FDA) shared its concerns about the design of Amgen’s study evaluating its experimental melanoma treatment, talimogene laherparepvec (T-VEC), however this did not sway the agency’s advisory panel, which voted overwhelmingly in favor of the drug candidate. The agency’s independent Oncologic Drugs Advisory …

Read More »

Study Finds Adaptive Biotechnologies’ Next-Generation Sequencing-Based Technology Can Detect Hodgkin Lymphoma Disease Recurrence

Adaptive Biotechnologies’ next-generation genetic diagnostic technology has demonstrated the potential to detect trace amounts of classical Hodgkin’s lymphoma (CHL) that remains in the body after treatment. Researchers at The University of Texas MD Anderson Cancer Center conducted a study showing that Adaptive Biotechnologies’ next-generation sequencing-based approach to identification and quantification …

Read More »

Celgene Inks Cancer Deals with Agios Pharmaceuticals and Northern Biologics

Celgene is enhancing its oncology pipeline, striking separate cancer-focused deals with Agios Pharmaceuticals and startup Northern Biologics. Agios announced it is expanding its partnership with cancer metabolism partner Celgene. The companies have entered into a new joint worldwide development and profit share collaboration for AG-881, a small molecule that has …

Read More »

Genmab and Novartis Announce Arzerra Meets Primary Endpoint in Late-Stage Study

Novartis and partner Genmab announced that Arzerra (ofatumumab) met its primary endpoint in a late-stage leukemia study. In separate announcements, the companies said that top-line results from the Phase III COMPLEMENT 2 study showed that treatment with Arzerra in combination with fludarabine and cyclophosphamide met the primary endpoint of improvement …

Read More »

Big Data’s Importance on Decision Making for Cancer Treatment Detailed by Cancer Experts

Big data plays a critical role in improving clinical decision making for patients with cancer, says cancer experts. Cancer experts have reported how a Varian Medical Systems supported project in the area of distributed learning is helping to harness the power of big data to benefit patients. Speakers at a …

Read More »

Celgene Acquires Cancer Biotech Quanticel Pharmaceuticals in $485 Million Deal

Celgene Corporation is expanding its pipeline of innovative cancer drugs, through its acquisition of privately-held biotech, Quanticel Pharmaceuticals. The companies announced today a definitive share purchase agreement under which Celgene will acquire Quanticel in exchange for its proprietary platform for the single-cell genomic analysis of human cancer, as well as …

Read More »